Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Heel pain: VAS 0 to 100 (higher scores = worse pain) ‐ short‐term · Adults with plantar heel pain¹
Local steroid injection showed no clear difference in heel pain: VAS 0 to 100 (higher scores = worse pain) ‐ short‐term compared with placebo or no treatment control (low certainty).
1 finding from 1 review
Heel pain: VAS 0 to 100 (higher scores = worse pain) ‐ medium‐term · Adults with plantar heel pain¹
Local steroid injection showed no clear difference in heel pain: VAS 0 to 100 (higher scores = worse pain) ‐ medium‐term compared with placebo or no treatment control (low certainty).
1 finding from 1 review
Function: medium‐term FFI (0 to 100: higher scores = worse function) FHSQ (0 to 100: higher scores = better function · Adults with plantar heel pain¹
It is very uncertain whether local steroid injection changes function: medium‐term FFI (0 to 100: higher scores = worse function)… compared with placebo or no treatment control (very low certainty).
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review
Return to previous level of activity or work · Adults with plantar heel pain¹
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events Short‐term · Adults with plantar heel pain¹
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure (Heel pain persists at 8 weeks; subsequent treatment at 12 weeks; no pain relief at 6 months) · Adults with plantar heel pain¹
It is very uncertain whether local steroid injection changes treatment failure (Heel pain persists at 8 weeks; subsequent… compared with placebo or no treatment control (very low certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in mean asthma symptom score Greater the reduction, better the outcome Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Intervention not reported
Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review